Canaccord raised the firm’s price target on Hims & Hers to $38 from $28 and keeps a Buy rating on the shares. The stock rallied 70% in November as Hims & Hers reported strong Q3 results, with revenue and profitability coming in well ahead of consensus estimates, the analyst tells investors in a research note. The firm says the company’s personalized dosing and frequent provider communication appears to be driving strong retention of weight loss prescriptions. Management emphasized that it remains confident that there is a path for the company to continue offering compounded personalized GLP-1 solutions even in an non-shortage environment, adds Canaccord.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HIMS:
- Trump Weekly: Autos, retail, restaurant sectors brace for import tariffs
- Hims & Hers rises 14.0%
- Trump Trade: Carmakers slip after 25% tariff threat on Mexico, Canada
- Hims & Hers (HIMS) Shares Surge 24% on Makary’s FDA Nomination
- BofA says FDA head nominee positive development for compounders like Hims & Hers